Harold A. Chapman, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Harold A. Chapman, MD

Professor, Department of Medicine, UCSF

Phone: (415) 353-2244 (appts)
Box 0130, UCSF
San Francisco, CA 94143-0130

View on UCSF Profiles

Cancer Center Membership

Associate Member » Cancer, Immunity, and Microenvironment

Research Summary

The Chapman lab has had a longstanding interest and track record of innovation in the field of tissue remodeling, particularly as it relates to lung disease. For many years my work primarily focused on proteolytic enzymes. My group and I cloned and characterized several new members of the cathepsin family and elucidated their roles in bone, brain, lung, and immune disorders. I also pursued basic mechanisms by which proteases and adhesion receptors coordinate cell invasion and extracellular matrix remodeling and this has led to longstanding interest in integrin signaling. We were the first to recognize the physical and functional connections between integrins and the key cell surface protease, plasminogen activator. After moving from Harvard to UCSF 12 years ago I focused my lab on pulmonary fibrosis as a disorder of great unmet medical need and a logical extension of my prior work in matrix biology. I pioneered the in vivo investigation of the role of epithelial mesenchymal transition (EMT) in pulmonary fibrosis and uncovered mechanistic insight as to how integrins and hypoxia regulate epithelial cell plasticity. These studies have provided a roadmap for defining the role of EMT signaling in human fibrosis and lung cancer. More recently we have extended our studies of epithelial plasticity into the realm of lung stem/progenitor cells and are committed to defining the regenerative potential of the lung after injury.

I have trained approximately twenty PhD and/or MD post-docs who now populate academic departments and pharmaceutical labs. As a physician scientist myself, I have particularly enjoyed the responsibility of motivating and training capable young physicians for careers in disease-oriented research. These now include Division and Department Chairs as well as several independent medicine faculty with successful NIH-funded research programs. My lab now is comprised of mainly PhD trainees and junior faculty and we are committed to understanding and targeting the emerging relationship between hypoxia, EMT, and tissue remodeling during fibrogenesis and cancer progression.

Education

Tulane University, 1968, Premedical
University of Alabama School of Medicine, M.D., 1972, Medicine


Professional Experience

  • 1972-1975
    Residency Training in Internal Medicine, University of Utah Affiliated Hospitals, Salt Lake City, UT
  • 1975-1977
    Associate Investigator, V.A. Medical Center, Salt Lake City, UT
  • 1978-1979
    Pulmonary Fellow, University of Utah Affiliated Hospitals, Salt Lake City, UT
  • 1979-1982
    Research Associate in Immunology, V.A. Medical Center, Salt Lake City, UT
  • 1979-1985
    Assistant Professor of Medicine, University of Utah, Department of Medicine, Salt Lake City, UT
  • 1985
    Associate Professor of Medicine, University of Utah, Department of Medicine, Salt Lake City UT
  • 1985-1999
    Associate Professor of Medicine, Harvard Medical School, Department of Medicine, Boston, MA
  • 1992-1999
    Physician, Brigham and Women's Hospital, Boston, MA
  • 1992-1999
    Associate Professor of Environmental Health, Harvard School of Public Health, Boston, MA
  • 2000
    Chief, Pulmonary and Critical Care Medicine Division, University of California, San Francisco
  • 2000
    Professor of Medicine, University of California, San Francisco
  • 2000
    Senior Member, Cardiovascular Research Institute, University of California San Francisco

Honors & Awards

  • 1972
    Alpha Omega Alpha, University of Alabama School of Medicine
  • 1985-1990
    Career Investigator Award, American Lung Association
  • 1987
    American Society for Clinical Investigation
  • 1998
    American Association of Physicians
  • 2001
    MERIT Award, NIH/NHLBI

Selected Publications

  1. Lineage-negative progenitors mobilize to regenerate lung epithelium after major injury. Nature. 2015 Jan 29; 517(7536):621-5.
    View on PubMed
  2. Innate Antiviral Host Defense Attenuates TGF-ß Function through IRF3-Mediated Suppression of Smad Signaling. Mol Cell. 2014 Dec 18; 56(6):723-37.
    View on PubMed
  3. Repair and regeneration of the respiratory system: complexity, plasticity, and mechanisms of lung stem cell function. Cell Stem Cell. 2014 Aug 7; 15(2):123-38.
    View on PubMed
  4. Soluble urokinase-type plasminogen activator receptor in FSGS: stirred but not shaken. J Am Soc Nephrol. 2014 Aug; 25(8):1611-3.
    View on PubMed
  5. Urokinase-type plasminogen activator receptor (uPAR) ligation induces a raft-localized integrin signaling switch that mediates the hypermotile phenotype of fibrotic fibroblasts. J Biol Chem. 2014 May 2; 289(18):12791-804.
    View on PubMed
  6. Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report. Am J Respir Crit Care Med. 2014 Jan 15; 189(2):214-22.
    View on PubMed
  7. Inhibition of epithelial-to-mesenchymal transition and pulmonary fibrosis by methacycline. Am J Respir Cell Mol Biol. 2014 Jan; 50(1):51-60.
    View on PubMed
  8. BPIFB1 is a lung-specific autoantigen associated with interstitial lung disease. Sci Transl Med. 2013 Oct 9; 5(206):206ra139.
    View on PubMed
  9. Activated alveolar epithelial cells initiate fibrosis through secretion of mesenchymal proteins. Am J Pathol. 2013 Nov; 183(5):1559-70.
    View on PubMed
  10. Cell therapy for lung diseases. Report from an NIH-NHLBI workshop, November 13-14, 2012. Am J Respir Crit Care Med. 2013 Aug 1; 188(3):370-5.
    View on PubMed
  11. Molecular determinants of lung development. Ann Am Thorac Soc. 2013 Apr; 10(2):S12-6.
    View on PubMed
  12. Cathepsin F mutations cause Type B Kufs disease, an adult-onset neuronal ceroid lipofuscinosis. Hum Mol Genet. 2013 Apr 1; 22(7):1417-23.
    View on PubMed
  13. Identification of pY654-ß-catenin as a critical co-factor in hypoxia-inducible factor-1a signaling and tumor responses to hypoxia. Oncogene. 2013 Oct 17; 32(42):5048-57.
    View on PubMed
  14. Regenerative activity of the lung after epithelial injury. Biochim Biophys Acta. 2013 Jul; 1832(7):922-30.
    View on PubMed
  15. Epithelial responses to lung injury: role of the extracellular matrix. Proc Am Thorac Soc. 2012 Jul; 9(3):89-95.
    View on PubMed
  16. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov. 2012 Mar; 2(3):270-87.
    View on PubMed
  17. Axin pathway activity regulates in vivo pY654-ß-catenin accumulation and pulmonary fibrosis. J Biol Chem. 2012 Feb 10; 287(7):5164-72.
    View on PubMed
  18. Integrin a6ß4 identifies an adult distal lung epithelial population with regenerative potential in mice. J Clin Invest. 2011 Jul; 121(7):2855-62.
    View on PubMed
  19. Cell plasticity in lung injury and repair: report from an NHLBI workshop, April 19-20, 2010. Proc Am Thorac Soc. 2011 Jun; 8(3):215-22.
    View on PubMed
  20. Toward lung regeneration. N Engl J Med. 2011 May 12; 364(19):1867-8.
    View on PubMed

Go to UCSF Profiles, powered by CTSI